The American Society of Clinical Oncology (ASCO) has recently updated its guidelines on the use of cannabis and cannabinoids for adults with cancer, shedding light on an area of growing interest and research within the medical community. With cannabis legalisation expanding in various parts of the world, both patients and healthcare providers are increasingly curious about its potential benefits in cancer care. The ASCO guidelines, as reported by PracticeUpdate, aim to provide a clear, evidence-based perspective on this topic.

Overview of the ASCO Guidelines

The guidelines are the result of a comprehensive systematic literature review, which encompassed 13 systematic reviews and 5 additional primary studies. This rigorous approach was designed to assess the current body of evidence regarding the effectiveness and safety of cannabis and cannabinoid use in cancer treatment. The findings indicate that, overall, the evidence supporting the benefits of cannabis and cannabinoids in cancer care is mostly of low certainty. There are two exceptions to this general conclusion, which are areas of very low or moderate certainty.

Key Recommendations

A notable recommendation from the ASCO guidelines is the potential utility of cannabis and cannabinoids in managing refractory, chemotherapy-induced nausea and vomiting. In such cases, these substances may be added to guideline-concordant antiemetic regimens. This recommendation stands out as one of the few instances where the guidelines endorse the use of cannabis or cannabinoids, highlighting their potential to improve quality of life for patients undergoing chemotherapy.

However, the guidelines also emphasise the lack of data supporting the use of cannabis or cannabinoids as anticancer treatments. While the exploration of these substances in oncology is encouraged, it is recommended to consider their use within the context of clinical trials. This cautious approach reflects the current understanding and acknowledges the need for more robust evidence before making broader recommendations.

Guidance for Clinicians

For clinicians, the ASCO guidelines offer practical advice on addressing cannabis use with patients. They suggest that healthcare providers should inquire about cannabis use and guide care accordingly or direct patients to appropriate resources. This proactive engagement is crucial, given the prevalence of cannabis use and the varying legal and regulatory landscapes across different regions.

The ASCO guidelines underscore the necessity for more research on the use of cannabis and cannabinoids in cancer treatment. Given the low certainty of the current evidence, there is a significant need for further studies to explore the potential benefits and risks. This call for research is particularly relevant in light of the growing interest among patients and the medical community in alternative and supplementary therapies for cancer care.

Conclusion

The updated ASCO guidelines on the use of cannabis and cannabinoids in adults with cancer provide a careful and evidence-based perspective on a complex issue. By highlighting the potential benefit for managing refractory, chemotherapy-induced nausea and vomiting and emphasising the lack of evidence for other uses, the guidelines serve as a valuable resource for oncology specialists. They balance optimism for future research with a prudent appraisal of the current state of evidence, guiding clinicians in their conversations with patients and in making informed decisions about treatment options.

The full details and recommendations of the ASCO guidelines can be explored through PracticeUpdate for those seeking to deepen their understanding of cannabis and cannabinoid use in cancer care.

Source

PracticeUpdate.